Phenotyping trailblazers are proving an impressive success in the clinic as the continue to go from strength to strength.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
People living in England will be the first in the world to have access to DNA tests as routine care starting this fall, putting the NHS at the forefront of healthcare, as it takes a huge step towards precision medicine.
Scientists have identified a molecular pathway that allows females to be more resilient to maternal stress than males which might explain why males are more at risk than females for neurodevelopmental disorders.
It doesn’t just seem like the world is experiencing more viral infections than before – it’s a reality. And the way humans live today helps viruses thrive.
For many women diagnosed with breast cancer, genetic testing can offer important information that might guide treatment choices. A new study finds that surgeons are a key influence.
New research links higher body fat with lower breast cancer risk before menopause.
“Artificial ovaries” are offering an alternative, safer, option for women that are infertile following chemotherapy treatment as for the first time ever, scientists have successfully isolated viable, early stage follicles in ovarian tissue scaffold in mice.
The discovery of molecular rules that regulate the transfer of genetic material between bacteria could help prevent the spread of antibiotic resistance.
A simple $20 blood test could help diagnose thousands of patients with hepatitis B in need of treatment in some of Africa’s poorest regions.
Researchers have discovered that men and women have different genetic risk factors for developing glioma.
Studies of breast cancer do not take sufficient account of patients’ race, ethnicity, economic status, education level, health insurance coverage, and other social factors, a group of scientists argue.